Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL975954 | 0.89 | MAPK1 (0.38) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL7497202 | 0.82 | MAPK1 (0.34) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL14270926 | 0.82 | EGLN2 (0.38) | KMT2AMEN1GAAALDH1A1TSHR | |
| SCHEMBL5746929 | 0.81 | HTT (0.39) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL3426566 | 0.81 | ALDH1A1 (0.36) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL4814986 | 0.81 | ALDH1A1 (0.38) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL3608660 | 0.80 | MAPK1 (0.37) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL29783525 | 0.80 | MAPK1 (0.37) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL79687 | 0.80 | MAPK1 (0.37) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL14338819 | 0.79 | MAPK1 (0.36) | MAPK1KMT2AMEN1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763622-B2 | Substituted 6-(2-halogennphenyl)-triazolopyrimidines | BASF AKTIENGESELLSCHAFT (DE) | 2010-07-27 | — | — | US | disclosed |
| US-20060241128-A1 | Substituted 6-(2-halogennphenyl)-triazolopyrimidines | BASF AKTIENGESELLSCHAFT (DE) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241128-A1 | Substituted 6-(2-halogennphenyl)-triazolopyrimidines | CBR3, CBR1, DCXR | MAPK1 2684/4885KMT2A 2591/4885MEN1 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.